To See Again (Advanced Cell Technology, Inc)
Wouldn’t it be great to be able to see perfectly again! There are millions of people in the world that would give anything to see with their eyes as they did before their eyesight worsened.
Advanced Cell Technology, Inc ( ACTC), is a biotech company that is committed to the field of regenerative medicine. ACTC engages in the development and commercialization of human embryonic and adult stem cell technology in the field of regenerative medicine. The company is conducting various clinical trials for treating macular degeneration, and has a preclinical development pipeline focused on products for eye diseases, autoimmune and inflammatory diseases, and wound healing. Its intellectual property portfolio includes pluripotent stem cell platforms comprising embryonic stem cell and induced pluripotent stem cell (iPSC) platforms; and other cell therapy research programs, such as ophthalmology, autoimmune/inflammation, and platelet program.
Back in 2012, two women with untreatable eye diseases said they had dramatic improvements in their vision after injections of human embryonic stem cells, making it the first documented time these controversial cells have helped someone. One woman said that before her stem cell surgery she couldn’t walk or cook by herself. After surgery that she had in one of her eyes, she was able to see to the point where she could cook again, walk on her own again, and even read again. Although we all need to be cautious about these results, it does appear to be an amazing event.
As I discussed in my previous article, biotech companies are the engines that create firepower that could fuel the world of preventive medicines and cures for diseases before the disease takes over our bodies. But as I also said, investing in biotech companies is a risky proposition. With risk comes reward. How much risk you are willing to take is your call. I’m only here to communicate some exciting things going on in the medical field.
The controversy is where these stem cells are coming from. According to ACTC, the stem cells for that study were derived from an embryo created in a fertility clinic by a couple that chose not to use it to create a pregnancy, said Gary Rabin, chief executive officer of Advanced Cell Technology, who said the couple donated the embryo to the company.
According to Dr. Robert Lanza, chief scientific officer at Advanced Cell Technology and a co-author of the study, the embryo was destroyed after the stem cells were derived, but in the future, doctors will be able to derive stem cells from an embryo without destroying it.
Back in 2009, Geron was the first company to get FDA approval for human trials using cells from embryonic stem cells, but in 2011, as a result of financial reasons, discontinued the effort.
ACTC is pushing forward with their efforts and maybe, just maybe they will develop a revolutionary treatment that will significantly improve an individuals eyesight. Just recently, a patient who was treated went from 20/400 eyesight to 20/40.
ACTC is currently trading at approx 0.07. As always, be a prudent investor and know the risk before investing.